Fintel reports that on December 15, 2025, Truist Securities initiated coverage of Septerna (NasdaqGM:SEPN) with a Buy ...
TipRanks on MSN
Septerna initiated with a buy at Truist
Truist initiated coverage of Septerna (SEPN) with a Buy rating and $34 price target The firm says the company’s SEP-631 is in Phase 1 for chronic ...
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...
Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback